Please login to read the full text of the article.
If you have no account yet, please register now.
Posted on
Previous Article
« Long-term safety and efficacy of ozanimod in RMS Next Article
Less thalamic atrophy in patients initiating ocrelizumab earlier »
« Long-term safety and efficacy of ozanimod in RMS Next Article
Less thalamic atrophy in patients initiating ocrelizumab earlier »
Table of Contents: MS Virtual 2020
Featured articles
COVID-19 and MS
Biomarkers
Treatment Strategies and Results
Management of progressive MS with approved DMT
Novel Treatment Directions
Neuromyelitis Optica Spectrum Disorders
Miscellaneous Topics
Related Articles
November 25, 2020
Outcomes in patients on alemtuzumab with thyroid adverse events

August 22, 2022
Ofatumumab improves cognitive processing speed
December 9, 2021
The role of astrocyte phenotypes in acute MS lesions
© 2021 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy